TGFB1 and neoplasm: All in all, the multifunctional IR‐TAM@Alb nanoparticles rather than the clinically used mono‐functional PD‐1, PD‐L1, or TGF‐β antibodies may be better used as an adjuvant to enhance the efficacy of tumor therapies in clinical in the future.